Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (for example, umbilical cord blood) and transplantation of older patients using less intense conditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are at risk for developing late complications secondary to pre-, peri- and post-transplant exposures and risk factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An international group of transplant experts was convened in 2011 to review contemporary literature and update the recommendations while considering the changing practice of transplantation and international applicability of these guidelines. This report provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT.
Your institute does not have access to this article
Open Access articles citing this article.
Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study
Stem Cell Research & Therapy Open Access 28 June 2022
Twenty years of experience of a tertiary cancer center in total body irradiation with focus on oncological outcome and secondary malignancies
Strahlentherapie und Onkologie Open Access 22 March 2022
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230–2239.
Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784–3792.
Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105: 4215–4222.
Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010; 28: 1888–1895.
Martin PJ, Counts Jr GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28: 1011–1016.
Majhail NS, Bajorunaite R, Lazarus HM, Wang Z, Klein JP, Zhang MJ et al. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol 2009; 147: 129–139.
Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006; 12: 138–151.
Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 2006; 37: 249–261.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant 2009; 44: 453–558.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143–1238.
Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009; 44: 521–526.
Welniak LA, Blazar BR, Murphy WJ . Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25: 139–170.
Machado CM, Martins TC, Colturato I, Leite MS, Simione AJ, Souza MP et al. Epidemiology of neglected tropical diseases in transplant recipients. Review of the literature and experience of a Brazilian HSCT center. Rev Inst Med Trop Sao Paulo 2009; 51: 309–324.
Gea-Banacloche J, Masur H, Arns da Cunha C, Chiller T, Kirchhoff LV, Shaw P et al. Regionally limited or rare infections: prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44: 489–494.
Wilson W, Taubert KA, Gewitz M, Lockhert PB, Baddour LM, Levison M et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116: 1736–1754.
Kim SK . Update on ocular graft versus host disease. Curr Opin Ophthalmol 2006; 17: 344–348.
Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415–419.
Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12: 375–396.
Baker KS, Gurney JG, Ness KK, Bhatia R, Forman SJ, Francisco L et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood 2004; 104: 1898–1906.
Benyunes MC, Sullivan KM, Deeg HJ, Mori M, Meyer W, Fisher L et al. Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys 1995; 32: 661–670.
Tichelli A, Gratwohl A, Egger T, Roth J, Prünte A, Nissen C et al. Cataract formation after bone marrow transplantation. Ann Intern Med 1993; 119: 1175–1180.
Meier JK, Wolff D, Pavletic S, Greinix H, Gosau M, Bertz H et al. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Investig 2011; 15: 127–139.
Pavletic SZ, Lee SJ, Socie G, Vogelsang G . Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant 2006; 38: 645–651.
Curtis RE, Metayer C, Rizzo JD, Socié G, Sobocinski KA, Flowers ME et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105: 3802–3811.
Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011; 117: 316–322.
Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175–1183.
Holtta P, Alaluusua S, Saarinen-Pihkala UM, Peltola J, Hovi L . Agenesis and microdontia of permanent teeth as late adverse effects after stem cell transplantation in young children. Cancer 2005; 103: 181–190.
Yen KT, Lee AS, Krowka MJ, Burger CD . Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med 2004; 25: 189–201.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.
Williams KM, Chien JW, Gladwin MT, Pavletic SZ . Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009; 302: 306–314.
Au BK, Au MA, Chien JW . Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1072–1078.
Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van 't Veer MB, Baaijens MH, de Boer JP et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 1878–1886.
Tichelli A, Bucher C, Rovo A, Stussi G, Stern M, Paulussen M et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007; 110: 3463–3471.
Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP . Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant 2001; 28: 101–103.
Griffith ML, Savani BN, Boord JB . Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 2010; 116: 1197–1204.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.
McDonald GB . Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010; 51: 1450–1460.
Barshes NR, Myers GD, Lee D, Karpen SJ, Lee TC, Patel AJ et al. Liver transplantation for severe hepatic graft-versus-host disease: an analysis of aggregate survival data. Liver Transpl 2005; 11: 525–531.
Peffault de Latour R, Levy V, Asselah T, Marcellin P, Scieux C, Adès L et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103: 1618–1624.
Majhail NS, Lazarus HM, Burns LJ . Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008; 41: 997–1003.
Hingorani S . Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol 2006; 17: 1995–2005.
Choi M, Sun CL, Kurian S, Carter A, Francisco L, Forman SJ et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. Cancer 2008; 113: 1580–1587.
Hingorani S, Guthrie KA, Schoch G, Weiss NS, McDonald GB . Chronic kidney disease in long-term survivors of hematopoietic cell transplant. Bone Marrow Transplant 2007; 39: 223–229.
Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ . Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 2005; 23: 6596–6606.
Herzberg PY, Heussner P, Mumm FH, Horak M, Hilgendorf I, von Harsdorf S et al. Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 1707–1717.
Couriel DR, Beguelin GZ, Giralt S, De Lima M, Hosing C, Kharfan-Dabaja MA et al. Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplant 2002; 30: 543–546.
Grauer O, Wolff D, Bertz H, Greinix H, Kühl JS, Lawitschka A et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain 2010; 133: 2852–2865.
McClune BL, Polgreen LE, Burmeister LA, Blaes AH, Mulrooney DA, Burns LJ et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant 2011; 46: 1–9.
Schulte CM, Beelen DW . Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. Blood 2004; 103: 3635–3643.
Yao S, McCarthy PL, Dunford LM, Roy DM, Brown K, Paplham P et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone Marrow Transplant 2008; 41: 393–398.
Savani BN, Donohue T, Kozanas E, Shenoy A, Singh AK, Childs RW et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 517–520.
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001; 44: 1496–1503.
Woo SB, Hellstein JW, Kalmar JR . Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753–761.
Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783–789.
McAvoy S, Baker KS, Mulrooney D, Blaes A, Arora M, Burns LJ et al. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16: 1231–1236.
Socie G, Cahn JY, Carmelo J, Vernant JP, Jouet JP, Ifrah N et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol 1997; 97: 865–870.
Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ, Straube A . Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 2003; 60: 842–848.
de Brabander C, Cornelissen J, Smitt PA, Vecht CJ, van den Bent MJ . Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatry 2000; 68: 36–40.
Tichelli A, Rovo A, Passweg J, Schwarze CP, Van Lint MT, Arat M et al. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol 2009; 2: 583–601.
Sostak P, Padovan CS, Eigenbrod S, Roeber S, Segerer S, Schankin C et al. Cerebral angiitis in four patients with chronic GVHD. Bone Marrow Transplant 2010; 45: 1181–1188.
Booth-Jones M, Jacobsen PB, Ransom S, Soety E . Characteristics and correlates of cognitive functioning following bone marrow transplantation. Bone Marrow Transplant 2005; 36: 695–702.
Syrjala KL, Artherholt SB, Kurland BF, Langer SL, Roth-Roemer S, Elrod JB et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol 2011; 29: 2397–2404.
Brennan BM, Shalet SM . Endocrine late effects after bone marrow transplant. Br J Haematol 2002; 118: 58–66.
Sanders JE, Hoffmeister PA, Woolfrey AE, Carpenter PA, Storer BE, Storb RF et al. Thyroid function following hematopoietic cell transplantation in children: 30 years’ experience. Blood 2009; 113: 306–308.
Ranke MB, Schwarze CP, Dopfer R, Klingebiel T, Scheel-Walter HG, Lang P et al. Late effects after stem cell transplantation (SCT) in children—growth and hormones. Bone Marrow Transplant 2005; 35 (Suppl 1): S77–S81.
Sanders JE . Endocrine complications of high-dose therapy with stem cell transplantation. Pediatr Transplant 2004; 8 (Suppl 5): 39–50.
Lee SJ, Flowers ME . Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008, 134–141.
Spinelli S, Chiodi S, Costantini S, Van Lint MT, Raiola AM, Ravera GB et al. Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica 2003; 88: 1163–1168.
Zantomio D, Grigg AP, MacGregor L, Panek-Hudson Y, Szer J, Ayton R . Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for management. Bone Marrow Transplant 2006; 38: 567–572.
Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003; 101: 2015–2023.
Landgren O, Gilbert ES, Rizzo JD, Socié G, Banks PM, Sobocinski KA et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992–5001.
Loren AW, Chow E, Jacobsohn DA, Gilleece M, Halter J, Joshi S et al. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant 2011; 17: 157–166.
Salooja N, Szydlo RM, Socie G, Rio B, Chatterjee R, Ljungman P et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001; 358: 271–276.
U.S. Preventive Services Task Force Child and Adolescent Recommendations. http://www.uspreventiveservicestaskforce.org/tfchildcat.htm (accessed 05/01/2011).
U.S. Preventive Services Task Force Recommendations for Adults. http://www.uspreventiveservicestaskforce.org/adultrec.htm (accessed 05/01/2011).
U.S. Preventive Services Task Force Screening for Osteoporosis, Topic Page. January 2011. http://www.uspreventiveservicestaskforce.org/uspstf/uspsoste.htm (accessed 08/01/2011).
US Department of Health and Human Services 2008 Physical activity guidelines for Americans www.health.gov (accessed 07/15/2011).
We acknowledge the following members of the Late Effects Working Group of the Asia-Pacific Blood and Marrow Transplantation Group for their review of this manuscript: Mickey Koh (Singapore), Jong Wook Lee (Korea), David Ma (Australia) and Tahir Shamsi (Pakistan).
Sources of support
The Center for International Blood and Marrow Transplant Research is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute, the National Heart, Lung and Blood Institute and the National Institute of Allergy and Infectious Diseases; a Grant/Cooperative Agreement 5U01HL069294 from the National Heart, Lung and Blood Institute and the National Cancer Institute; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from AABB; Allos Inc.; Amgen Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US Inc.; Be the Match Foundation; Biogen IDEC; BioMarin Pharmaceutical Inc.; Biovitrum AB; BloodCenter of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; ClinImmune Labs; CTI Clinical Trial and Consulting Services; Eisai Inc.; Genentech Inc.; Genzyme Corporation; Histogenetics Inc.; HKS Medical Information Systems; Hospira Inc.; Kirin Brewery Co. Ltd; The Leukemia & Lymphoma Society; Merck & Company; The Medical College of Wisconsin; Millennium Pharmaceuticals Inc.; Miller Pharmacal Group; Milliman USA Inc.; Miltenyi Biotec Inc.; National Marrow Donor Program; Nature Publishing Group; Novartis Oncology; Oncology Nursing Society; Osiris Therapeutics Inc.; Otsuka America Pharmaceutical Inc.; Pall Life Sciences; Pfizer Inc.; Schering Corporation; Sigma-Tau Pharmaceuticals; Soligenix Inc.; StemCyte Inc.; StemSoft Software Inc.; Sysmex America Inc.; THERAKOS Inc.; Vidacare Corporation; ViraCor Laboratories; ViroPharma Inc.; and Wellpoint Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense or any other agency of the US Government.
The authors declare no conflict of interest.
Supplementary Information accompanies the paper on Bone Marrow Transplantation website
About this article
Cite this article
Majhail, N., Rizzo, J., Lee, S. et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 47, 337–341 (2012). https://doi.org/10.1038/bmt.2012.5
- hematopoietic cell transplantation
- late complications
Mesenchymal stromal cell treatment improves outcomes in children with pneumonia post-hematopoietic stem cell transplantation: a retrospective cohort study
Stem Cell Research & Therapy (2022)
Bone Marrow Transplantation (2022)
Variations in provision of psychological care to hematopoietic cell transplant recipients: results of a national survey of UK transplant centers
Bone Marrow Transplantation (2022)
Long-term treatment burden following allogeneic blood and marrow transplantation in NSW, Australia: a cross-sectional survey
Journal of Cancer Survivorship (2022)
Changes in the health-related quality of life and social reintegration status after lung transplantation following hematopoietic stem cell transplantation
Supportive Care in Cancer (2022)